BridgeMD
Tests treatment safety and results for Erythematous Telangiectatic Rosacea
Official title Efficacy and Safety Evaluation of CICAPLAST BAUME B5+ on Rosacea Accompanied by Sensitive Skin
ClinicalTrials.gov ID: NCT07106957
What this study is testing
- What it's testing
- In total, 72 eligible research participants were recruited in this 56-day study. The participants were divided into two groups-namely the Experimental Group and the Control Group-according to stratified randomization, with 36 participants in each group.
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 55
You may be able to join if
- 18-55 years old
- Participants in the rosacea erythematous telangiectasia study or participants in the rosacea erythematous telangiectasia study who have not received...
- The score of the Persistent Erythema Assessment Scale (CEA) is between 1 and 3 points
- The score of the Global Assessment Scale (IGA) is ≤2 points
- Dry facial skin
You likely can't join if
- Intending to get pregnant, pregnant, lactating or within 6 months of delivery
- Research participants with other facial skin diseases (such as seborrheic dermatitis, systemic lupus erythematosus, facial miliform lupus, contact...
- Systemic diseases accompanied by severe organ damage, malignant tumors, chronic diseases with unstable control, acute infectious diseases, major...
- The test area is accompanied by other skin diseases (dermatitis, eczema, infection, tumor, etc.) or has other skin conditions that interfere with...
- Received physical, chemical or laser cosmetic surgery that is not for rosacea treatment within 3 months
- Subject who has participated in any clinical test during the past 2 month
See the full eligibility criteria
- 18-55 years old
- Participants in the rosacea erythematous telangiectasia study or participants in the rosacea erythematous telangiectasia study who have not received treatment or have received treatment but are currently in a stable...
- The score of the Persistent Erythema Assessment Scale (CEA) is between 1 and 3 points
- The score of the Global Assessment Scale (IGA) is ≤2 points
- Dry facial skin
- People with sensitive skin (10% of those sensitive to lactic acid stinging)
- Intending to get pregnant, pregnant, lactating or within 6 months of delivery
- Research participants with other facial skin diseases (such as seborrheic dermatitis, systemic lupus erythematosus, facial miliform lupus, contact dermatitis, hormone-dependent dermatitis, etc.)
- Systemic diseases accompanied by severe organ damage, malignant tumors, chronic diseases with unstable control, acute infectious diseases, major surgeries or traumas, psychological and mental disorders, or other...
- The test area is accompanied by other skin diseases (dermatitis, eczema, infection, tumor, etc.) or has other skin conditions that interfere with evaluation (birthmarks, scars, etc.)
- Received physical, chemical or laser cosmetic surgery that is not for rosacea treatment within 3 months
- Subject who has participated in any clinical test during the past 2 month
- Others whose participation in the study is determined inappropriate by the dermatologist
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.